Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer
TP53 C-LOH GCs with genomic instability and immune evasion phenotype have poor clinical outcomes in patients treated with ACT or immunotherapy.
Authors
- Ruochen Li (ORCID: https://orcid.org/0000-0003-4013-3281)
- Jieti Wang
- Jiejie Xu (ORCID: https://orcid.org/0000-0001-7431-9063)
- Yun Gu (ORCID: https://orcid.org/0000-0001-6942-0749)
- Mengyao Sun (ORCID: https://orcid.org/0009-0001-2239-3170)
- Fei Shao (ORCID: https://orcid.org/0000-0002-8742-9197)
- Hongyong He (ORCID: https://orcid.org/0000-0001-7371-4133)
- Li He (ORCID: https://orcid.org/0000-0001-9313-1218)
- Hanji Fang
- Heng Zhang (ORCID: https://orcid.org/0000-0001-6404-5396)
- Hao Liu (ORCID: https://orcid.org/0000-0002-1792-9209)
- Chao Lin (ORCID: https://orcid.org/0000-0003-2800-0208)
Institutions
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shanghai First People's Hospital (CN)
- Shanghai Sixth People's Hospital (CN)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1038/s41416-024-02825-1
- Citations
- 10
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Fudan University
- Natural Science Foundation of Fujian Province
- Shanghai Rising-Star Program